ARS Pharmaceuticals, Inc. — Director's Dealing 2023

Oct 2, 2023

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: ARS Pharmaceuticals, Inc. (SPRY)
CIK: 0001671858
Period of Report: 2023-09-28

Reporting Person: Fitzpatrick Alexander A (Chief Legal Officer)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2023-09-28	Common Stock	P	40000	$3.624	Acquired	42969	Direct
2023-09-29	Common Stock	P	46258	$3.783	Acquired	89227	Direct

Footnotes

F1: The price reported in Column 4 is the weighted average price. The shares were purchased in multiple transactions at prices ranging from $3.60 to $3.64, inclusive. Upon request by the Securities and Exchange Commission staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares purchased at each separate price will be provided.

F2: Includes 2,969 shares acquired under the Issuer's 2020 Employee Stock Purchase Plan on June 30, 2023.

F3: The price reported in Column 4 is the weighted average price. The shares were purchased in multiple transactions at prices ranging from $3.70 to $3.85, inclusive. Upon request by the Securities and Exchange Commission staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares purchased at each separate price will be provided.